MADRIGAL PHARMACEUTICALS INC. - COMMON STOCK

Madrigal Pharmaceuticals Announces New Data from the Phase 3 MAESTRO-NASH Study of Rezdiffra™ (resmetirom) Presented at the EASL Congress

06 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates

07 May 2024 06:00:01 By Nasdaq GlobeNewswire

Madrigal Statement on the Passing of Dr. Stephen Harrison

24 Apr 2024 15:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024

23 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

16 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces U.S. Availability of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic NASH with Moderate to Advanced Liver Fibrosis

09 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Apr 2024 15:05:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Pricing of Upsized $600 Million Public Offering

18 Mar 2024 22:58:56 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Proposed Public Offering

18 Mar 2024 15:04:05 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces FDA Approval of Rezdiffra™ (resmetirom) for the Treatment of Patients with Noncirrhotic Nonalcoholic Steatohepatitis (NASH) with Moderate to Advanced Liver Fibrosis

14 Mar 2024 15:15:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Mar 2024 15:05:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces EMA Validation of its Marketing Authorization Application for Resmetirom for the Treatment of NASH/MASH with Liver Fibrosis

05 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Appoints Mardi C. Dier as Chief Financial Officer

28 Feb 2024 06:01:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results

28 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

21 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Publication of the Phase 3 MAESTRO-NASH Trial of Resmetirom in the New England Journal of Medicine

08 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

06 Feb 2024 15:05:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Announces Additions to Its Leadership Team

29 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

22 Jan 2024 07:00:00 By Nasdaq GlobeNewswire